Meeting
2022 ASCO Annual Meeting
Lemzoparlimab (lemzo) with venetoclax (ven) and/or azacitidine (aza) in patients (pts) with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS): A phase 1b dose escalation study.
Authors
Naval Guastad Daver
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Naval Guastad Daver , Don A. Stevens , Jing-Zhou Hou , Takahiro Yamauchi , Yakir Moshe , Chun Yew Fong , Angela Marzocchetti , Ryan Adamec , Maulik Patel , Stacie Lambert , Kevin Wu , Christoph Röllig
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT04912063
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS7067)
DOI
10.1200/JCO.2022.40.16_suppl.TPS7067
Abstract #
TPS7067
Poster Bd #
296a
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies.
First Author: Curtis Andrew Lachowiez
Poster
2021 ASCO Annual Meeting
Comparison of dose modification strategies to address expected hematologic toxicities in treatment-naïve higher-risk (HR) MDS patients treated with venetoclax + azacitidine.
First Author: Jacqueline Suen Garcia
Poster
2018 ASCO Annual Meeting
Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naïve higher-risk myelodysplastic syndromes.
First Author: Chun Yew Fong
Poster
2023 ASCO Annual Meeting
Phase 1 dose escalation study of DSP107, a first-in-class CD47 and 4-1BB targeting fusion protein, in combination with atezolizumab in patients with advanced solid tumors.
First Author: Anwaar Saeed